Mayo Clinic

Monoclonal antibody therapy for COVID-19 safe, effective for transplant patients

Newswise — ROCHESTER, Minn. — Treating transplant patients with mild to moderate cases of COVID-19 with monoclonal antibodies is safe and helps prevent serious illness, according to a Mayo Clinic study recently published in Open Forum Infectious Diseases. These results are especially important because transplant patients who are infected with COVID-19 have a higher risk of severe illness and death.

"Monoclonal antibody therapy is really important for the transplant population because they are less likely to develop their own immunity. Providing them with these antibodies helps them recover from COVID-19," says Raymund Razonable, M.D., a Mayo Clinic infectious diseases specialist and the study's senior author.

The retrospective study focused on the first 73 solid organ transplant patients who received monoclonal antibody infusions for treatment of mild to moderate COVID-19 between Nov. 19, 2020, and Jan. 23 at Mayo Clinic. Eleven patients had an emergency department visit and nine patients were hospitalized. Most significantly, no patients required mechanical ventilation, died or experienced organ rejection.

"While we expected monoclonal antibody therapy would be beneficial for patients, we were pleasantly surprised by the results. Only one patient required care in the ICU for non-COVID-19 indication, and, most importantly, there were no deaths," Dr. Razonable says.

Monoclonal antibodies help prevent the virus that causes COVID-19 from attaching to human cells, which helps block the spread of infection. In fall 2020, the Food and Drug Administration authorized the emergency use of bamlanivimab and casirivimab-imdevimab to treat mild to moderate COVID-19 in patients with a high risk of becoming seriously ill. But since the safety and efficacy of these therapies for transplant patients remained unknown due to the limited clinical data, many health care institutions initially hesitated to set up infusion centers, Dr. Razonable says.

The study's results highlight the important role monoclonal antibodies can play in treating transplant patients with mild to moderate COVID-19. Knowing how best to treat these patients remains crucial given that recent studies indicate that COVID-19 vaccines are not as effective for transplant patients.

"It is important that these patients have early access to monoclonal antibody treatment," Dr. Razonable says. "Our data show the outcomes for patients are better if they get infused earlier." The study's lead author is Zachary Yetmar, M.D., Mayo Clinic. Other co-authors are Elena Beam, M.D.Jack O'Horo, M.D.Ravindra Ganesh, M.B.B.S., M.D.Dennis Bierle, M.D.Lisa Brumble, M.D.; and Teresa Seville, M.D. ― all of Mayo Clinic.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. For information on COVID-19, including Mayo Clinic's Coronavirus Map tracking tool, which has 14-day forecasting on COVID-19 trends, visit the Mayo Clinic COVID-19 Resource Center.                                                              

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 6054
access_time Embargo lifts in 2 days
Embargo will expire: 26-Jul-2021 11:00 AM EDT Released to reporters: 23-Jul-2021 5:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Jul-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: NIH Chooses University of Miami Miller School of Medicine to Head Project for Its Safe Return to In-Person School Initiative
Released: 23-Jul-2021 12:15 PM EDT
NIH Chooses University of Miami Miller School of Medicine to Head Project for Its Safe Return to In-Person School Initiative
University of Miami Health System, Miller School of Medicine

The University of Miami Miller School of Medicine is helping to lead a National Institutes of Health (NIH) COVID-19 testing initiative to safely return children to in-person school.

Released: 23-Jul-2021 11:40 AM EDT
New 'Atlas' Charts How Antibodies Attack Spike Protein Variants
Brigham and Women’s Hospital

As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus.

23-Jul-2021 8:55 AM EDT
COVID Variants and a Surge Among the Unvaccinated: Live Expert Panel for July 23rd, 2021
Newswise

Panelists will discuss the threat posed by new COVID variants and continued vaccine hesitancy.

Released: 22-Jul-2021 4:05 PM EDT
COVID-19: Patients with Malnutrition May Be More Likely to Have Severe Outcomes
Scientific Reports

Adults and children with COVID-19 who have a history of malnutrition may have an increased likelihood of death and the need for mechanical ventilation, according to a study published in Scientific Reports.

access_time Embargo lifts in 2 days
Embargo will expire: 27-Jul-2021 4:05 PM EDT Released to reporters: 22-Jul-2021 3:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 27-Jul-2021 4:05 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 26-Jul-2021 4:05 PM EDT Released to reporters: 22-Jul-2021 2:45 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Jul-2021 4:05 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 22-Jul-2021 2:35 PM EDT
New Insights Into Uncontrolled Inflammation in COVID-19 Patients
Queen Mary University of London

In a new study, published recently in the journal Circulation Research, scientists discover how the production of protective molecules known as specialised pro-resolving mediators (SPM) is altered in patients with COVID-19.

Released: 22-Jul-2021 2:30 PM EDT
度假旅行者需要了解的COVID-19相关信息
Mayo Clinic

许多人会利用国家法定假日出门旅行或举办聚会。由于仍有许多人需要接种COVID-19疫苗以及传染性更强的Delta变种疫苗,因此健康专家建议,如果您计划旅行或召集很多人聚会,请务必谨慎。


Showing results

110 of 6054

close
1.41954